Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Condition(s) studied
Investigational drug(s) / intervention(s)
Inclisiran: Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
Study summary
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
Eligibility
Primary outcome measure(s)
- Percentage change in LDL-C from baseline to 10 months — Baseline, 10 months
Percentage change in Low density lipoprotein - Cholesterol (LDL-C)
Trial sites (38)
| Facility | City | Region | Status |
|---|---|---|---|
| Novartis Investigative Site | Feldkirch | Austria | |
| Novartis Investigative Site | Graz | Austria | |
| Novartis Investigative Site | Linz | Austria | |
| Novartis Investigative Site | Sankt Veit im Pongau | Austria | |
| Novartis Investigative Site | Vienna | Austria | |
| Novartis Investigative Site | Vienna | Austria | |
| Novartis Investigative Site | Shenzhen | Guangdong | |
| Novartis Investigative Site | Holon | Gush Dan | |
| Novartis Investigative Site | Petah Tikva | Israel | |
| Novartis Investigative Site | Tel Aviv | Israel | |
| Novartis Investigative Site | Kuala Lumpur | Kuala Lumpur | |
| Novartis Investigative Site | Kuala Lumpur | Malaysia | |
| Novartis Investigative Site | Riyadh | Saudi | |
| Novartis Investigative Site | Jeddah | Saudi Arabia | |
| Novartis Investigative Site | Tabuk | Saudi Arabia | |
| Novartis Investigative Site | Fribourg | CH | |
| Novartis Investigative Site | Basel | Switzerland | |
| Novartis Investigative Site | Geneva | Switzerland | |
| Novartis Investigative Site | Lausanne | Switzerland | |
| Novartis Investigative Site | Olten | Switzerland | |
| Novartis Investigative Site | Sankt Gallen | Switzerland | |
| Novartis Investigative Site | Zurich | Switzerland | |
| Novartis Investigative Site | Zurich | Switzerland | |
| Novartis Investigative Site | Dubai | United Arab Emirates | |
| Novartis Investigative Site | Abu Dhabi | United Arab Emirates | |
| Novartis Investigative Site | Al Ain City | United Arab Emirates | |
| Novartis Investigative Site | Dubai | United Arab Emirates | |
| Novartis Investigative Site | High Wycombe | Buckinghamshire | |
| Novartis Investigative Site | Louth | Lincolnshire | |
| Novartis Investigative Site | Sunderland | Tyne and Wear | |
| Novartis Investigative Site | Belfast | United Kingdom | |
| Novartis Investigative Site | Bromwich | United Kingdom | |
| Novartis Investigative Site | Burton-on-Trent | United Kingdom | |
| Novartis Investigative Site | Hull | United Kingdom | |
| Novartis Investigative Site | Lancaster | United Kingdom | |
| Novartis Investigative Site | Liverpool | United Kingdom | |
| Novartis Investigative Site | London | United Kingdom | |
| Novartis Investigative Site | Middlesex | United Kingdom |
On this site
📄 Leqvio (inclisiran) drug profile →More Novartis Pharmaceuticals trials in the UK
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05399992 on ClinicalTrials.gov ↗ ← All trials in the UK